Action NOVO NORDISK A/S
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Novo Nordisk A/S Xetra

Actions

DK0060102614

Cours en clôture Xetra
Autres places de cotation
- EUR - Graphique intraday de Novo Nordisk A/S
06/06 Vers l'infini et au-delà Our Logo
06/06 Les actions européennes progressent grâce aux valeurs technologiques à l'approche de la décision de la BCE RE

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
AQ
Novo Nordisk A/S - share repurchase programme
GL
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
AQ
Novo Nordisk A/S - share repurchase programme
GL
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
AQ
Novo Nordisk A/S - share repurchase programme
GL
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GL
Novo Nordisk A/S: Once-weekly and once-monthly Mim8 demonstrate superior reduction of treated bleeding episodes compared to on-demand and prior prophylaxis treatment in people with haemophilia A in the Frontier 2 trial
GL
Tampere University : Novo Nordisk Foundation grants 670 000 EUR to develop organ transplant assessment and drug discovery tool for epilepsy
AQ
Equity Research | NANEXA: Insights from CMD underscore near- to mid-term opportunities with significant potential
AQ
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GL
FORGET HANDBAGS, OZEMPIC'S IN
AQ
Trading in Novo Nordisk shares by board members, executives and associated persons
GL
Novo Nordisk A/S - share repurchase programme
GL
Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme
GL
Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk
AQ
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GL
Nanexa publishes interim report for January-March 2024
AQ
Weight-loss drug Wegovy available in Canada starting May 6 for people with obesity
AQ
Novo Nordisk A/S : Go to the Q1 2024 company announcement
PU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NOVO B
  4. Action
  5. Actualités Novo Nordisk A/S
  6. Communiqués